期刊文献+

采用S/D病毒灭活后凝血酶原复合物在犬非停滞模型上致血栓性的研究 被引量:1

Study on Thrombogenicity of Prothrombin Complex Concentrate Post Inactivation of Virus by S/D in Non stasis Canine Model
下载PDF
导出
摘要 目的:进一步评价采用有机溶剂/表面活性剂(S/D)技术灭活病毒后新工艺凝血酶原复合物(PCC)的潜在致血栓性。方法:采用犬非停滞模型进行实验研究,动态监测血小板数(即刻测定),D-二聚体、TXB2、FⅤ∶C、FⅧ∶C、蛋白C和PT7项指标,并与未经病毒灭活处理的旧工艺PCC进行比较。结果:新工艺PCC组的上述指标动态变化所表明的潜在血栓倾向均明显低于旧工艺PCC组。结论:经病毒灭活处理的新工艺PCC不但病毒安全性已提高,其血栓形成的危险性也明显降低。 To evaluate further the potential thrombogenicity of the prothrombin complex concentrate(PCC) produced by new technological process with virus inactivation by S/D technique.Method:The experimental study was carried out in non stasis canine model,meanwhile the dynamic monitoring of the following seven indices was performed:platelete count(determinated immediately),D dimer,thromboxane B 2(TXB 2),factor V activity,factor Ⅷ activity,protein C activity and partial thromboplastin time(PT),and the new prothrombin complex concentrate was compared with the old one produced by technological process without virus inactivation treatment by S/D in respect of potential thrombogenicity.Results:The potential thrombogenic tendency of new prothrombin complex concentrate showed by dynamic changes of their indices mentioned above was obviously better than that of the old one.Conclusion:The new prothrombin complex concentrate not only has higher safety in terms of virus infection,but also has obviously lower risk of thrombogenicity.
出处 《中国输血杂志》 CAS CSCD 北大核心 1999年第1期5-8,共4页 Chinese Journal of Blood Transfusion
基金 中国医学科学院中国协和医科大学科研基金
关键词 凝血酶原复合物 血栓性 犬非停滞模型 prothrombin complex concentrate Thrombosis Non stasis canine model
  • 相关文献

参考文献4

二级参考文献1

共引文献132

同被引文献30

  • 1余蓉,赵青蓉,杜俊蓉.不同工艺凝血酶原复合物在兔停滞模型中致血栓性的比较研究[J].中国实验血液学杂志,1996,4(4):416-418. 被引量:2
  • 2Chandra S, Brummelhuis HGJ. Prothrombin complex concentrates for clinical use. Vox Sang,1981,41 (4) :257-273.
  • 3Lorenz R, Kienast J, Otto U, et al. Efficacy and safety of a prothrombin complex concentrates with two virus-inactivation steps in patients with severe liver damage. Eur J Gastroenterol Hepatol, 2003,15(1) : 15-20.
  • 4Hbert Bohrer. Prothrombin complex concentrate substitution during liver transplantation. Thromb Res, 1999, 95 ( Suppl 4) S71 -74.
  • 5Lusher JM, Shapiro SS, Palascak JE, et al. Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to Factor Ⅷ. A multicenter therapeutic trial. New Eng J Med, 1980, 303 (8) :421-425.
  • 6Lankiewicz MW, Hays J, Friedman KD, et al. Urgent reversal of warfarin with prothrombin complex concentrate. Thromb Haemost, 2006,4 (5) :967-970.
  • 7Huttner HB, Schellinger PD, Hartmann M, et al. Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: comparison of acute treatment strategies using vitamin K, freash frozen plasma, and prothrombin complex concentrates. Stroke, 2006,37 (6) :1465-1470.
  • 8Godier A. Alternatives to fresh frozen plasma: protheombin complex concentrate and transfusion guidelines. Macan : ISBT. JUNE 7-12,2008.
  • 9Kohler M. Thrombogenicity of prothrombin complex concentrates. Thromb Res, 1999,95 ( S1 ) : 13-17.
  • 10Giles AR, Nesheim ME, Hoogendoom H. et al. The coagulant-active phospholipids content is a major determinant of in vivo thrombogenicity of prothrombin complex (factoriX) concentrates in rabbits. Blood, 1982,59(2) :401-407.

引证文献1

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部